



Supplemental Material to:

Takenori Ogawa, Thomas E. Liggett, Anatoliy A. Melnikov, Constance L. Monitto, Daniela Kusuke, Kiyoto Shiga, Toshimitsu Kobayashi, Akira Horii, Aditi Chatterjee, Victor V. Levenson, Wayne Koch, David Sidransky and Xiaofei Chang. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.



Cell Cycle 2012; 11(8).

<http://www.landesbioscience.com/journals/cc/article/20120/>

a. Cetuximab



b. Erlotinib



Supplemental Figure 1 : The response of parental and acquired resistant daughter cells to cetuximab (a), or erlotinib (b).